Truist Financial’s 4D Molecular Therapeutics FDMT Stock Holding History
Bought
Maintained
Sold
Other funds holding FDMT
Truist Financial's FDMT Position: Q3 2026 in Review
Truist Financial held its 4D Molecular Therapeutics (FDMT) position steady in Q3 2026 at 25,000 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #2407.
Truist Financial first reported a position in FDMT in Q4 2025 and has held it in 4 quarters since. 167 funds tracked by Wall St. Rank hold FDMT as of Q3 2026.
- Truist Financial held 25,000 shares of 4D Molecular Therapeutics worth $358K as of Q3 2026.
- Truist Financial left its 4D Molecular Therapeutics share count unchanged in Q3 2026.
- 4D Molecular Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q3 2026, its #2407 holding.
- Truist Financial first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 4 quarters since.
- 167 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2026.
Based on Truist Financial's 13F filing for Q3 2026, filed 30 Oct 2026.